Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Care situation for rare diseases

Many affected people are still in childhood

    • Allergology and clinical immunology
    • Infectiology
    • News
    • Oncology
    • Pediatrics
    • RX
  • 3 minute read

How are rare diseases defined in the first place and what is the epidemiological situation in Switzerland? In principle, a condition is considered rare or neglected if no more than one in 2000 people have it. Taken together, such diseases affect nearly half a million people in Switzerland alone. What is certain is that both the diagnostic and therapeutic situation for those affected must be improved.

(ag) If you take all the diseases that fall into the category of “rare disease” together, you get about 7000. Of these, only about 15% are being researched. In Switzerland, more than 400,000 and in the entire EU about 30 million people suffer from this disease. people at one of these entities, which puts the word “rare” into perspective. A particularly large number of those affected are still in childhood. This is not surprising, since a large number of rare diseases, which can include a failure of metabolic or organ functions as well as impaired defense and delayed growth, are caused by a defect in the genetic material. The average of affected children dies before the age of ten.

The diagnosis is difficult

Naturally, only a few physicians specialize in a particular rare disease at a time, resulting in delayed diagnosis. Even improved technical possibilities in the field of blood and genetic testing, e.g. for rare metabolic diseases, cannot compensate for this circumstance. Therefore, patients, physicians, researchers and other experts must be networked internationally to ensure communication in favor of faster diagnosis and thus more effective therapy. Especially for inclusion in studies, there are often too few participants in a single country. It therefore makes little sense for Switzerland to act alone in this area and, as has been the case to date, to network only to a limited extent internationally. It is more than understandable and quite beneficial if the population informs itself about rare diseases, because this also lowers the hurdle for a conversation with the doctor and makes the correct diagnosis more likely. The earlier such a condition is detected (and communication is fundamental to this), the higher the treatment benefit in terms of quality of life and expectancy. National competence centers could also help to improve the situation (not least in the area of health insurance reimbursement decisions as reported in HAUSARZT PRAXIS 5/2014). Examples from abroad show how this can be done in an exemplary manner.

Cure impossible

Although a cure is still not possible for the vast majority of rare diseases (in the case of rare diseases of the nervous system, sometimes not even progression can be prevented), early therapy starts are crucial. The first Swiss foundation for rare diseases, Foundation Orphanbiotec, is one of these players active in the field of rare diseases and drug development. It is the initiator of a hybrid model. While the independent, nonprofit foundation educates about rare diseases, gives patients a voice, networks and raises money from the public, the associated social enterprise conducts research to develop new orphan drugs. This is intended to jointly finance drugs and reduce start-up risks for impact investors (the focus is on substances of natural origin). Part of the company’s profit, if any, flows back into the foundation to initiate new projects.

Support also needed from the authorities

However, in order to be able to develop and produce new and affordable drugs for those affected, support is also needed from the authorities. Italy, for example, requires all pharmaceutical companies to give five percent of their marketing expenditures to drug research in this area. This example could also be used in Switzerland for sustainable research success and to support those affected. This is where the traditional pharmaceutical industry can make a direct contribution to society.

HAUSARZT PRAXIS 2014; 9(6): 46-47

Partner
  • 20151013_orphan-logo_de
Autoren
  • Andreas Grossmann
Publikation
  • HAUSARZT PRAXIS
Related Topics
  • rare diseases
Previous Article
  • Physician prescription of physical activities

Careful planning is indicated

  • News
  • Physical medicine and rehabilitation
  • Prevention and health care
  • RX
  • Sports Medicine
View Post
Next Article
  • SAKK publication

Cancer patients receive different regional treatment at the end of their lives

  • Oncology
  • Prevention and health care
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 4 min
  • Guideline update

Dietary recommendations for Crohn’s disease and colitis

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.